Ishita Drugs & Industries Limited will hold a board meeting on Tuesday, September 22, 2026, to consider raising funds. The company intends to secure working capital and project term loan facilities during the session.

The meeting is scheduled pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The agenda includes approving the terms and conditions for these financial facilities.

Key Agenda Items

The board will focus on the following matters:

• Consider and approve raising of funds by way of working capital and project term loan facilities.
• Approve the terms and conditions for the same.
• Any other matter with permission of the chair.

Jagdish Agrawal, Managing Director, signed the intimation notice dated September 18, 2026. The company is headquartered in Ahmedabad.

Ishita Drugs & Industries Ltd has scheduled its 33rd Annual General Meeting for Wednesday, September 30, 2026. The board confirmed the schedule in a filing with the Bombay Stock Exchange on August 27, 2026.

The meeting will be held at 11:30 am at "Manthan", Hotel Krsna Lila, in Sanand, Gujarat. Shareholders eligible as of the record date will be able to cast their votes electronically during the designated window.

Book Closure and Voting Schedule

The register of members and share transfer books will remain closed from September 24, 2026, to September 30, 2026, both days inclusive. This period determines eligibility for the AGM.

The company will utilize the services of National Securities Depository Limited (NSDL) for the electronic voting process. The e-voting period runs from Sunday, September 27, 2026, through Tuesday, September 29, 2026.

AGM Agenda Items

The notice outlines ordinary and special business to be transacted during the meeting.

Ordinary Business:

• Adoption of audited financial statements for FY26.
• Re-appointment of M/s Jaymin Shah & Associates as statutory auditors.
• Approval of related-party transactions with Ishita Pharmaceuticals.
• Approval of related-party transactions with Anvi Lifesciences Private Limited.

Special Business:

• Re-appointment of Mrs. Abha Agrawal as a Non-Executive Non-Independent Director post attaining the age of 75 years.

Mrs. Agrawal, a promoter associated with the company for over 30 years, retires by rotation. The board recommends her re-appointment citing her extensive experience in business matters and governance oversight.

The related-party transactions involve sales, purchases, leasing, and services with Ishita Pharmaceuticals and Anvi Lifesciences Private Limited. These entities are linked to key management personnel, including Managing Director Jagdish Agrawal and CFO Sumit Agrawal. The transactions are expected to exceed 10% of the company's annual turnover, necessitating shareholder approval under SEBI (LODR) Regulations.

Regulatory Compliance and Shareholder Communication

The intimation was issued in accordance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Jagdish Agrawal, Managing Director of Ishita Drugs & Industries Ltd, signed the communication.

In compliance with Regulation 36(1)(b) of the Listing Regulations, the company issued letters providing a weblink to the Annual Report and AGM Notice for shareholders who have not registered their email addresses with the Registrar and Share Transfer Agents or Depository Participants. The dispatch of these inland letters was completed on August 27, 2026, covering 3,069 consignments via Net Air Express Couriers.

Shareholders are advised to check their eligibility on the NSDL platform during the specified window to ensure their votes are recorded before the deadline.